TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in fluency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of geriatric trauma
Endpoint domain: Mortality/survival
Primary endpoint: Behavioural Regulations in Exercise Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incident unintended pregnancy
Endpoint domain: Adverse events/effects
Primary endpoint: Combustible cigarette use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects after radiotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Scrupulosity Obsessions and Compulsions Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Experiential Avoidance Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Unsuccessful transition
Endpoint domain: Adverse events/effects
Primary endpoint: GI-2 Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Jebsen-Taylor Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moberg pick-up test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Lactobacillus crispatus-dominant microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barthel Index Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hand held dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Willingness to use little cigars cigarillos (LCCs)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in perceived stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in size of the warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment-related adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Time to ART attrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detectable viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red blood cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: White blood cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measures of taste and smell
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of pressure pain threshold in the perineum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of pelvic floor muscle tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of ambulatory blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cadence of walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion in the lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RTW/work continuation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence and severity of adverse device effects (ADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Median time to re-epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 5-years Recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mepolizumab serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VL first attempt success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: POD-postoperative delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal adverse outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Cessation of Bleeding up to 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Device and Procedure-related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: anti-SARS-CoV-2 antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T cell memory responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of delay between diagnosis of CDI and elimination of C. difficile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pathological response rate (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective response rate assessed by MRI (RECIST1.1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dialysis Diet and Fluid Restriction Compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Flow cytometric quantification of cell populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of sulcal pits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of Parkinson's Disease
Endpoint domain: Mortality/survival
Primary endpoint: Sexual Debut/Ever Sex (Vaginal)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Sexual Debut/Ever Sex (Anal)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Sexual Debut/Ever Sex (Oral)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Success rate of spleen stiffness measurement exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutralizing antibody against SARS-CoV-2 wild type and variants of concern (VOCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SRAS-CoV-2 S protein-binding antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reward Prediction Error Brain Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Suck effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of Life in Neurological Disorders (Neuro-QoL) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Likelihood of patient referral
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Consumption of postoperative morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Birth Companion Coverage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Systemic Pro-inflammatory Cytokine Levels (IL-6, IL-1ra, C-reactive Protein [CRP], sTNFαRII)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of General Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracheal sound measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to sustained COVID-19 Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six-Minute Walk Test (6 MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biceps Curl Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate of Confirmed Herpes Zoster Cases
Endpoint domain: Adverse events/effects
Primary endpoint: Global Rank Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to Achieve Medical Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean memory test composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in mean executive test composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of patients who accessed CT and NG management
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant satisfaction with a pharmacy-based CT and NG management program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number and proportion of CT and NG tests with positive results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for Rescue Surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Pain scores before injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores after injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient perception of freeze spray efficacy in decreasing anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Current overall status compared to pre-injection baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hepatitis B surface antigen seroclearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 12 item Short Form Survey (SF-12)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sciatica Bothersomeness Index (SBI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak dysmenorrhea NRS during menstrual period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood gases sample interpretation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini-Mental State Examination (MMS) Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Endothelial Glycocalyx Examination in Donors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial Glycocalyx Examination in Recipients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with haemorrhagic events and complications
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life in children with asthma
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sensitivity of liquid biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychosocial risk factors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy of ultrasound measurement of hyomental distance ratio (HMDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in T cell infiltration in tumor biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Digoxin and Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve from Hour 0 to the Last Measurable Concentration (AUC0-t) of Digoxin and Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cmax (Tmax) of Digoxin and Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device related Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurophysiological measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of first-line immunotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: duration of the infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Oral Morphine Equivalent - Opioid Usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone health outcomes
Primary endpoint: Change in Health-related Quality of Life (HRQOL) - PedsQL 4.0
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Health-related Quality of Life (HRQOL) - PedsQL 3.0
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in global longitudinal strain (GLS%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in left ventricular ejection fraction (LVEF%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite of left bundle branch area pacing lead septal myocardial or coronary artery perforation, lead dislodgment, and repeat procedures related to left bundle branch area lead implantation
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Changes in Drug Use Frequency and Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Changes in Mental Health Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean changes in depression severity as measured by the Patient Health Questionnaire-9 (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Posttraumatic Stress Disorder Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isokinetic eccentric maximal strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal arm exercises capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5D Itch Scale score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in alpha power from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sleep Quality from baseline
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Rates of sex without a contraceptive method
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Use of preferred contraceptive method
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentage of incomplete salpingectomies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Knee extension in mid stance (KEMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative change from baseline in UACR at 180 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Presence of unsolicited immediate systemic adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of medically attended AEs (MAAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of serious AEs (SAEs) and AEs of special interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Social Isolation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Mood_hedonic Tone
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Histological clearance of treated isSCC lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dose Limiting Toxicity (DLT) of Pirtobrutinib
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Pirtobrutinib Versus Placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attention and working memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Steps Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minutes of Moderate-to-Vigorous Activity Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total active range of motion (AROM) of the affected finger
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from Integra or BTM treated burns to autograft procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Vancouver Scar Scale assessment of tissue quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain, Enjoyment, General activity (PEG) composite score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: hypoglycemia percentage of time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Action Naming Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Extracellular vesicle/exosome content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in stimulation sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach the cecum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent of patients receiving high quality care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: whole unstimulated sialometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: salivary gland ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of 18F- Fluciclovine pelvic PET/MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PWMC Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of treatment sessions attended by parents
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Treatment acceptability/satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinician adherence to ADAPT protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of enrolled participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Dental discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful DISE procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of exam results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Select Treatment-related Toxicities (TRT) in Arm B
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Adverse Events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Unified Parkinson's Disease Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Central lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lateral lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of LUS for the detection of TB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of LUS for the detection of TB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of FASH PLUS for the detection of TB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of FASH PLUS for the detection of TB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of combined LUS and FASH PLUS features for the detection of TB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity and specificity of the combined PAD assessment tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose tolerability response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TD-600 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Suicide Risk as Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants with Local Pain at the Site of Injection Assessed Using the Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Return to Work - International Physical Activity Questionnaire (IPAQ) Scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Ostomy output reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of ultrasonographical abnormal lung signatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients with desaturation < 85 percent during intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ventilatory frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: TcPCO2 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Use of the device
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Serotonin transporter pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain molecular pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serotonin release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Variation of the spectral power in the α band (8-12 Hz) of the EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Nasal Polyp Score (NPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life - Global Health Status
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life